Indication
T-Cell Lymphoma
10 clinical trials
12 products
1 drug
Product
CTX130Clinical trial
A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Relapsed or Refractory T or B Cell MalignanciesStatus: Active (not recruiting), Estimated PCD: 2027-03-01
Clinical trial
An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients With Refractory or Relapsed Non-Cutaneous CD4+ T-Cell LymphomaStatus: Completed, Estimated PCD: 2006-01-01
Product
HuMax-CD4Product
TenalisibProduct
RomidepsinClinical trial
An Open Label, Phase I/II Study to Evaluate the Safety and Efficacy of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor Given in Combination With a Histone Deacetylase (HDAC) Inhibitor, Romidepsin in Adult Patients With Relapsed/Refractory T-cell LymphomaStatus: Completed, Estimated PCD: 2021-05-14
Clinical trial
Long-term Follow-up of Patients Previously Treated With Autologous T Cells Genetically Modified With Viral VectorsStatus: , Estimated PCD: 2043-07-01
Product
AUTO CAR T cell therapyClinical trial
PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell LymphomaStatus: Not yet recruiting, Estimated PCD: 2026-10-01
Clinical trial
Multicenter, Open Label, Phase I/II of Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper PhenotypeStatus: Recruiting, Estimated PCD: 2026-12-31
Product
ACHOPClinical trial
A Real-world Study: Efficacy and Safety of Selinexor-based Regimens for Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2024-10-10
Drug
SelinexorClinical trial
A Single-arm, Multi-center Phase II Clinical Study on Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma.Status: Not yet recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Multicenter, Single-arm, Open Clinical Efficacy Observational Study of Cidapenem Combined With Azacitidine and Mitoxantrone Liposome (CAM) Regimen for Relapsed/Refractory Intra-nodal Follicular Adjuvant T-cell Lymphoma (nTFHL)Status: Not yet recruiting, Estimated PCD: 2023-12-01
Product
CidapenemClinical trial
A Phase II Single Arm Proof of Concept, Safety, Efficacy, Multicenter Study of Brentuximab Vedotin as Consolidation Therapy After Autologous Stem Cell Transplant in CD30 Expressing Peripheral T Cell LymphomasStatus: Withdrawn, Estimated PCD: 2022-12-14
Product
Brentuximab Vedotin